Journal
NANOMEDICINE
Volume 5, Issue 4, Pages 597-615Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.10.35
Keywords
Brij; drug delivery; efflux transporters; lipid formulation; nanoparticle; P-glycoprotein; Pluronic; vitamin E TPGS
Funding
- NIH [R01 CA115197]
Ask authors/readers for more resources
Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available